cPMP Stabilizes MoCo Pathway for Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological inflammatory diseases such as ALS, epilepsy, and schizophrenia are inadequate in addressing the underlying neural circuit dyshomeostasis and synaptic inhibition dysregulation caused by inflammatory cytokines, leading to hyperexcitability and seizures.
Innovation Solution
Administration of cyclic pyranopterin monophosphate (cPMP) to stabilize the molybdenum cofactor (MoCo) synthesis pathway, overriding dyshomeostasis and controlling synaptic inhibition by stabilizing inhibitory synapses, thereby reducing neural circuit hyperactivity and seizure symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurological inflammatory diseases, then current standard therapies are applied, but they fail to address underlying neural circuit dyshomeostasis and synaptic inhibition dysregulation
Solution Approach 1:
cPMP serves as an intermediary substance that mediates between the dysregulated MoCo synthesis pathway and synaptic inhibition. By providing exogenous cPMP, the treatment bypasses the defective endogenous synthesis pathway and directly restores MoCo levels, thereby stabilizing inhibitory synapses and addressing the root cause of neural circuit dyshomeostasis rather than merely treating symptoms
Solution Approach 2:
The treatment leverages the body's existing biochemical pathways by providing cPMP, which is then processed through the MoCo synthesis pathway to restore endogenous MoCo production. This allows the body's own metabolic systems to correct the dyshomeostasis without requiring external intervention beyond the initial cPMP supplementation
2Reliability
If cPMP is administered to stabilize MoCo synthesis pathway, then synaptic inhibition is controlled and neural circuit hyperactivity is reduced, but this represents a novel strategy requiring validation
Solution Approach 1:
The treatment changes the biochemical parameter of MoCo synthesis by providing exogenous cPMP, which shifts the equilibrium of the MoCo synthesis pathway toward increased MoCo production. This parameter change propagates through the system to stabilize synaptic inhibition and reduce neural hyperexcitability, achieving complex therapeutic effects through a single biochemical parameter modification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
cPMP effectively renormalizes inhibitory synaptic function, reducing seizure activity and alleviating symptoms of neurological inflammatory diseases by modulating the MoCo biosynthetic pathway and restoring homeostasis in neural networks.
Implementation Method 1
Administration of cyclic pyranopterin monophosphate (cPMP) to stabilize the molybdenum cofactor (MoCo) synthesis pathway, overriding dyshomeostasis
Implementation Method 2
cPMP effectively renormalizes inhibitory synaptic function, reducing seizure activity and alleviating symptoms of neurological inflammatory diseases by modulating the MoCo biosynthetic pathway and restoring homeostasis in neural networks
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Methods of treating neurological inflammatory disease or seizures caused by neuroinflammation by administering cPMP are described. Treating neuroinflammatory and neurometabolic diseases with cPMP is described so as to override dyshomeostasis in the MoCo synthesis pathway and control synaptic inhibition in the gephyrin-GABAR pathway.